Sbir phase II: endoluminal fixation of a distraction enterogenesis device

Active Project Grant Awarded Last action

Award ID
2232550
Recipient
Awarding agency
Obligated
$1,470,358

Award facts

Completion date 88% complete
Originally
Place of performance
Mountain View, CA 94040, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The broader impact/commercial potential of this small business innovation research (SBIR) phase II project is the advancement of an innovative therapy for short bowel syndrome. Compared to current non-curative treatments that are chronic and associated with dangerous complications, rehospitalization, and high mortality, the proposed solution has the potential to substantially improve outcomes and quality-of-life for patients and their families. The potential commercial impact of this project is likewise substantial. Treating short bowel syndrome currently costs hundreds of thousands of dollars per patient per year. Adds more than $5 billion to US healthcare expenditures annually. Thus, the proposed curative solution can lead to enormous savings in dollars and in specialists? Time. This small business innovation research (SBIR) phase II project will create a curative therapy for patients with short bowel syndrome, which is currently managed with intravenous nutrition and lacks effective treatments. The proposed solution will lengthen the intestine, increasing the absorptive surface area and restoring the natural function of the GUT, enabling patients to get sufficient nutrition from the food they eat. The proposed system comprises nondestructive tissue anchors and a spring that pushes against them to stretch the intestine and force IT to grow. Having previously developed the tissue anchors, this project develops a delivery method that will allow the system to be implanted in the intestine through a minimally invasive procedure. Feedback will be gathered from pediatric gastroenterologists and surgeons about the delivery method, and device performance will be measured in pre-clinical large-animal studies. Successful completion of the proposed project will demonstrate intestinal lengthening in vivo, achieved via a minimally invasive procedure, and establish a foundation for planning subsequent preclinical testing that will be required for regulatory approval to commercialize the product. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.

Transactions

Action Obligated Date
Amendment $499,874
Original award $970,484

Quick answers

Who received award 2232550?

2232550 was awarded to Eclipse Regenesis, Inc. by National Science Foundation on May 1, 2023.

How much is award 2232550 worth?

$1,470,358 has been obligated on 2232550.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login